CN108697759B - 补体活性的调节剂 - Google Patents

补体活性的调节剂 Download PDF

Info

Publication number
CN108697759B
CN108697759B CN201680081854.4A CN201680081854A CN108697759B CN 108697759 B CN108697759 B CN 108697759B CN 201680081854 A CN201680081854 A CN 201680081854A CN 108697759 B CN108697759 B CN 108697759B
Authority
CN
China
Prior art keywords
administration
complement
subject
pharmaceutical composition
hemolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680081854.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108697759A (zh
Inventor
S·J·德马科
M·D·霍尔蒂
G·V·帕克
A·里卡多
S·托比
D·A·特雷科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Inc
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Priority to CN202210878127.8A priority Critical patent/CN115920000B/zh
Publication of CN108697759A publication Critical patent/CN108697759A/zh
Application granted granted Critical
Publication of CN108697759B publication Critical patent/CN108697759B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN201680081854.4A 2015-12-16 2016-12-07 补体活性的调节剂 Active CN108697759B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210878127.8A CN115920000B (zh) 2015-12-16 2016-12-07 补体活性的调节剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562268360P 2015-12-16 2015-12-16
US62/268,360 2015-12-16
US201662331320P 2016-05-03 2016-05-03
US62/331,320 2016-05-03
US201662347486P 2016-06-08 2016-06-08
US62/347,486 2016-06-08
PCT/US2016/065228 WO2017105939A1 (en) 2015-12-16 2016-12-07 Modulators of complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210878127.8A Division CN115920000B (zh) 2015-12-16 2016-12-07 补体活性的调节剂

Publications (2)

Publication Number Publication Date
CN108697759A CN108697759A (zh) 2018-10-23
CN108697759B true CN108697759B (zh) 2022-08-02

Family

ID=57758701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680081854.4A Active CN108697759B (zh) 2015-12-16 2016-12-07 补体活性的调节剂
CN202210878127.8A Active CN115920000B (zh) 2015-12-16 2016-12-07 补体活性的调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210878127.8A Active CN115920000B (zh) 2015-12-16 2016-12-07 补体活性的调节剂

Country Status (26)

Country Link
US (3) US10835574B2 (enExample)
EP (3) EP3389692B1 (enExample)
JP (3) JP7126940B2 (enExample)
KR (1) KR20180094913A (enExample)
CN (2) CN108697759B (enExample)
AU (1) AU2016370210A1 (enExample)
BR (1) BR112018012174A2 (enExample)
CA (1) CA3007772A1 (enExample)
CY (1) CY1123031T1 (enExample)
DK (2) DK3685847T5 (enExample)
ES (2) ES2941640T3 (enExample)
FI (1) FI3685847T3 (enExample)
HR (2) HRP20200508T1 (enExample)
HU (1) HUE061759T2 (enExample)
IL (1) IL259762B (enExample)
LT (2) LT3389692T (enExample)
MX (2) MX2018007352A (enExample)
PL (2) PL3685847T3 (enExample)
PT (2) PT3685847T (enExample)
RS (2) RS64067B1 (enExample)
RU (2) RU2733720C2 (enExample)
SG (1) SG11201804721SA (enExample)
SI (2) SI3389692T1 (enExample)
SM (1) SMT202000213T1 (enExample)
TW (2) TWI745320B (enExample)
WO (1) WO2017105939A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
US12240893B2 (en) * 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
ES2973767T3 (es) * 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
ES3013485T3 (en) 2019-09-12 2025-04-14 Ra Pharmaceuticals Inc Treatment of a neurological disease with complement inhibitors
KR20230017789A (ko) 2020-04-30 2023-02-06 알닐람 파마슈티칼스 인코포레이티드 보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
EP4423273A1 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CN103347895A (zh) * 2010-10-01 2013-10-09 阿雷克森制药公司 与人补体成分c5结合的多肽
CN103561765A (zh) * 2011-05-05 2014-02-05 沃尔斯塔特免疫疗法公司 补体因子b类似物及其用途
CN104231085A (zh) * 2013-09-05 2014-12-24 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
JPH08510325A (ja) 1993-05-28 1996-10-29 カイロン コーポレイション 生物学的に活性なペプチド配列の選択方法
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69739163D1 (de) 1996-10-17 2009-01-22 Mitsubishi Chem Corp Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
WO2000007979A2 (en) 1998-08-07 2000-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
JP4768620B2 (ja) 2003-05-15 2011-09-07 ジェネンテック， インコーポレイテッド 敗血症の予防及び治療のための方法及び組成物
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
WO2006105214A2 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
EP2129681A2 (en) 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
WO2008137236A2 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
MX2010003630A (es) 2007-10-02 2010-04-21 Potentia Pharmaceuticals Inc Administracion sostenida de analogos de compstatina desde geles.
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
CN105413022A (zh) * 2011-03-29 2016-03-23 艾伯维公司 自动注射装置中的改进的护罩展开
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
WO2013052736A2 (en) 2011-10-06 2013-04-11 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (es) * 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
EP3119802B1 (en) 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
KR101981532B1 (ko) * 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
CN107427482A (zh) 2015-01-21 2017-12-01 帕西拉制药有限公司 凝血酸的多囊脂质体制剂
PL3250230T3 (pl) * 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
RU2733720C2 (ru) * 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2019051436A1 (en) 2017-09-11 2019-03-14 Ra Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CN103347895A (zh) * 2010-10-01 2013-10-09 阿雷克森制药公司 与人补体成分c5结合的多肽
CN103561765A (zh) * 2011-05-05 2014-02-05 沃尔斯塔特免疫疗法公司 补体因子b类似物及其用途
CN104231085A (zh) * 2013-09-05 2014-12-24 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of RA101348, a Potent Cyclic Peptide Inhibitor of C5for Complement-Mediated Diseases;Alonso Ricardo等;《BLOOD》;20141206;第124卷(第21期);全文 *
Preclinical Evaluation of RA101495, a Potent Cyclic PeptideInhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria;Alonso Ricardo等;《BLOOD》;20151203;第126卷(第23期);全文 *

Also Published As

Publication number Publication date
US20250090624A1 (en) 2025-03-20
RU2018121615A (ru) 2020-01-20
JP7126940B2 (ja) 2022-08-29
CY1123031T1 (el) 2021-10-29
JP2024001300A (ja) 2024-01-09
IL259762A (en) 2018-07-31
EP4218790A1 (en) 2023-08-02
RU2020131790A (ru) 2020-10-20
MX2022013454A (es) 2023-02-22
RU2018121615A3 (enExample) 2020-03-16
CA3007772A1 (en) 2017-06-22
BR112018012174A2 (pt) 2018-12-04
US11752190B2 (en) 2023-09-12
TW201733609A (zh) 2017-10-01
HRP20200508T1 (hr) 2020-09-04
LT3389692T (lt) 2020-04-27
FI3685847T3 (fi) 2023-04-03
TW202200189A (zh) 2022-01-01
DK3389692T3 (da) 2020-03-30
AU2016370210A1 (en) 2018-06-21
ES2781551T3 (es) 2020-09-03
ES2941640T3 (es) 2023-05-24
US20180369322A1 (en) 2018-12-27
WO2017105939A1 (en) 2017-06-22
PL3389692T3 (pl) 2020-06-15
RS64067B1 (sr) 2023-04-28
SI3685847T1 (sl) 2023-05-31
CN108697759A (zh) 2018-10-23
KR20180094913A (ko) 2018-08-24
HRP20230182T1 (hr) 2023-04-14
DK3685847T5 (da) 2024-08-26
CN115920000B (zh) 2025-04-25
JP7379615B2 (ja) 2023-11-14
EP4218790A8 (en) 2023-10-04
SI3389692T1 (sl) 2020-07-31
SG11201804721SA (en) 2018-07-30
LT3685847T (lt) 2023-03-27
EP3389692B1 (en) 2020-03-04
JP2019504012A (ja) 2019-02-14
RU2020131790A3 (enExample) 2021-11-18
IL259762B (en) 2020-06-30
CN115920000A (zh) 2023-04-07
DK3685847T3 (da) 2023-02-27
PT3685847T (pt) 2023-03-14
RS60134B1 (sr) 2020-05-29
TWI779805B (zh) 2022-10-01
RU2733720C2 (ru) 2020-10-06
PT3389692T (pt) 2020-04-07
PL3685847T3 (pl) 2023-05-08
SMT202000213T1 (it) 2020-05-08
MX2018007352A (es) 2019-05-16
US10835574B2 (en) 2020-11-17
EP3389692A1 (en) 2018-10-24
JP2022159479A (ja) 2022-10-17
EP3685847A1 (en) 2020-07-29
US20210077572A1 (en) 2021-03-18
TWI745320B (zh) 2021-11-11
HUE061759T2 (hu) 2023-08-28
RU2769701C2 (ru) 2022-04-05
EP3685847B1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
JP7379615B2 (ja) 補体活性のモジュレーター
US11723949B2 (en) Modulators of complement activity
US20210000927A1 (en) Modulators of complement activity
HK40084222A (en) Modulators of complement activity
HK40031446A (en) Modulators of complement activity
HK40031446B (en) Modulators of complement activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant